 Rubius Therapeutics Inc NASDAQ: RUBY stock is trading after reporting initial data from its ongoing Phase 12 trial of RTX-240 in patients with advanced solid tumors. Initial efficacy results showed a confirmed partial response PR with a 54 reduction in the target lesions in a patient with metastatic anal cancer whose disease had progressed on anti-PD-L1 therapy. 